Trial · NCT03197935
Results by group334
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 334
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population | Placebo and Chemotherapy | 69 | Number of Participants | ||
| Number of Participants With Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population | Atezolizumab and Chemotherapy | 95 | Number of Participants | ||
| Number of Participants With pCR in Subpopulation With PD-L1-Positive Tumor Status (Tumor-infiltrating Immune Cell [IC] 1/2/3) Using AJCC Staging System | Placebo and Chemotherapy | 37 | Number of Participants | ||
| Number of Participants With pCR in Subpopulation With PD-L1-Positive Tumor Status (Tumor-infiltrating Immune Cell [IC] 1/2/3) Using AJCC Staging System | Atezolizumab and Chemotherapy | 53 | Number of Participants | ||
| Event-Free Survival (EFS) in All Participants | Placebo and Chemotherapy | NA | 95% Confidence Interval NA to NA | Months | |
| Event-Free Survival (EFS) in All Participants | Atezolizumab and Chemotherapy | NA | 95% Confidence Interval NA to NA | Months | |
| Event-Free Survival (EFS) in Subpopulation With PD-L1-Postive Tumor Status | Placebo and Chemotherapy | NA | 95% Confidence Interval NA to NA | Months | |
| Event-Free Survival (EFS) in Subpopulation With PD-L1-Postive Tumor Status | Atezolizumab and Chemotherapy | NA | 95% Confidence Interval NA to NA | Months | |
| Disease-Free Survival (DFS) in All Participants Who Undergo Surgery | Placebo and Chemotherapy | NA | 95% Confidence Interval NA to NA | Months | |
| Disease-Free Survival (DFS) in All Participants Who Undergo Surgery | Atezolizumab and Chemotherapy | NA | 95% Confidence Interval NA to NA | Months | |
| Disease-Free Survival (DFS) in Subpopulation of Participants With PD-L1-Positive Tumor Status Who Undergo Surgery | Placebo and Chemotherapy | NA | 95% Confidence Interval NA to NA | Months | |
| Disease-Free Survival (DFS) in Subpopulation of Participants With PD-L1-Positive Tumor Status Who Undergo Surgery | Atezolizumab and Chemotherapy | NA | 95% Confidence Interval NA to NA | Months | |
| Overall Survival (OS) in All Participants | Placebo and Chemotherapy | NA | 95% Confidence Interval NA to NA | Months | |
| Overall Survival (OS) in All Participants | Atezolizumab and Chemotherapy | NA | 95% Confidence Interval NA to NA | Months | |
| Overall Survival (OS) in Subpopulation With PD-L1-Positive Tumor Status | Placebo and Chemotherapy | NA | 95% Confidence Interval NA to NA | Months | |
| Overall Survival (OS) in Subpopulation With PD-L1-Positive Tumor Status | Atezolizumab and Chemotherapy | NA | 95% Confidence Interval NA to NA | Months | |
| Mean Scores for Function (Role/Physical) and GHS/HRQoL by Cycle and Between Treatment Arms as Assessed by the EORTC QLQ-C30 | Placebo and Chemotherapy | GHS/QoL Baseline | 76.45 | 95% Confidence Interval 73.47 to 79.42 | Score on a 0-100 scale |
| Mean Scores for Function (Role/Physical) and GHS/HRQoL by Cycle and Between Treatment Arms as Assessed by the EORTC QLQ-C30 | Atezolizumab and Chemotherapy | GHS/QoL Baseline | 79.24 | 95% Confidence Interval 76.34 to 82.14 | Score on a 0-100 scale |
| Mean Scores for Function (Role/Physical) and GHS/HRQoL by Cycle and Between Treatment Arms as Assessed by the EORTC QLQ-C30 | Placebo and Chemotherapy | GHS/QoL Cycle 2 Day 1 | 71.90 | 95% Confidence Interval 69.04 to 74.76 | Score on a 0-100 scale |
| Mean Scores for Function (Role/Physical) and GHS/HRQoL by Cycle and Between Treatment Arms as Assessed by the EORTC QLQ-C30 | Atezolizumab and Chemotherapy | GHS/QoL Cycle 2 Day 1 | 71.55 | 95% Confidence Interval 68.53 to 74.57 | Score on a 0-100 scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03197935/results